2/26/2010

The FDA postponed its deadline for reviewing Theratechnologies' drug tesamorelin to July 27 after a panel meeting was moved to May 27. The drugmaker submitted tesamorelin for approval to treat excess abdominal fat in HIV-positive patients.

Full Story:
Reuters

Related Summaries